Archives
-
Commercial SARS-CoV-2 Libraries: A Critical Review
2026-10-02
Kralj, Jukić, and Bren critically evaluated commercial SARS-CoV-2-targeted, protease-focused, and protein–protein interaction inhibitor libraries for virtual screening. Their central finding is that broad commercial availability is not matched by sufficient disclosure of library design, docking protocols, chemical-space analysis, or compound-level validation, limiting confidence in downstream drug-design decisions.
-
Streptavidin – Cy5 for Cell Assay Readouts
2026-10-01
This scenario-based guide explains how Streptavidin – Cy5 (SKU K1080) can support biotin-based fluorescence detection in viability, proliferation, apoptosis, immunofluorescence, and flow cytometry workflows. It connects the reagent’s documented binding and optical specifications with practical controls, storage, interpretation, and vendor-selection decisions.
-
DiscoveryProbe Protease Inhibitor Library Workflow
2026-10-01
Build reproducible biochemical and cell-based screens around 825 pre-dissolved compounds spanning cysteine, serine, and proteasome-associated protease targets. The workflow combines concentration-controlled protease inhibition with orthogonal readouts for apoptosis, cancer research, and infectious disease research.
-
Polymeric Nanoplatform Activates STING in TAMs
2026-09-30
Li et al. developed a mannose-modified, pH-responsive polymeric nanoplatform that co-delivers R848 and cGAMP to tumor-associated macrophages. The study links STING activation with fatty acid oxidation, SIRPα downregulation, enhanced phagocytosis, and improved responses to CD47 and PD-L1 blockade in preclinical melanoma models.
-
Reserpine N1867: Practical Workflow
2026-09-30
Reserpine (SKU N1867) provides a defined research reagent for workflows that require controlled handling of a potent bioactive natural product, including neurotransmitter depletion research and neuropharmacology research. It is intended for laboratory use only and should not be used for diagnosis, treatment, or clinical management of hypertension.
-
Angiotensin 1/2 (5-7) Experimental Guide
2026-09-29
Build reproducible cardiovascular and receptor-binding assays around a defined H2N-Ile-His-Pro-OH peptide. This guide connects practical peptide handling with an emerging SARS-CoV-2 spike–receptor binding application while separating established product specifications from exploratory workflow recommendations.
-
Native Protein Gel Electrophoresis with K4142
2026-09-29
Discover how the Basic Protein Native PAGE Gel Preparation and Electrophoresis Kit supports activity-preserving separation of acidic proteins. This guide also translates a VHL-deficient renal cancer study into practical assay-design decisions without overstating what native PAGE can prove.
-
Network Medicine Identifies Apigenin for Alzheimer’s
2026-09-28
A 2025 study used network proximity analysis to screen flavonoids against Alzheimer’s disease targets and identified Apigenin as the strongest candidate among four experimentally validated compounds. Cell-based experiments linked its neuroprotective activity to mitochondrial preservation, reduced apoptosis, AKT/NF-κB pathway modulation, and microglial polarization.
-
Light-Gated Translation for Regulated Gene Therapy
2026-09-28
The study introduces a rationally designed light-inducible RNA-releasing protein (LIRP) that suppresses mRNA translation in darkness and permits expression under blue or ambient light. In mouse models, LIRP-regulated AAV gene switches enabled light-responsive interventions in skin and retina, suggesting a way to make some gene therapies more controllable while leaving important questions about clinical translation open.
-
GDC-0941 in Cancer Signaling: Beyond Viability
2026-09-27
Explore how GDC-0941, a potent PI3K inhibitor, can help researchers distinguish acute pathway engagement from changes in cancer-cell behavior. A phenotype-aware framework connects PI3K/Akt measurements with recent findings on pancreatic cancer plasticity—without overstating what the evidence shows.
-
AG-120 and the IDH1 Leukemia Feedback Loop
2026-09-26
AG-120 (Ivosidenib) lowers mutant IDH1-derived 2-hydroxyglutarate, but the biology around that metabolite extends beyond enzyme inhibition. This article examines how CD44-dependent metabolic rewiring may shape leukemia-cell dependence, pharmacodynamic interpretation, and combination research.
-
DNase I (RNase-free) for Cleaner RNA Workflows
2026-09-25
Remove DNA without sacrificing RNA integrity: learn how to place ribonuclease-free DNase I in RNA extraction, RT-PCR, and in vitro transcription workflows. A practical pilot design, assay controls, and troubleshooting guidance help you optimize digestion without assuming an unverified enzyme dose.
-
A High-Throughput Surrogate Model for BBB Permeability
2026-09-25
Hu and colleagues developed a Transwell blood–brain barrier surrogate using LLC-PK1-MOCK and LLC-PK1-MDR1 cells, then tested it against 41 compounds and in vivo brain-distribution data. Their findings highlight a useful combination of P-glycoprotein efflux assessment and lysosomal-trapping correction, while also defining important limits on how a simplified epithelial model should be interpreted.
-
Arachidonic Acid Enhances Vaccine Humoral Immunity
2026-09-24
The study reports that dietary arachidonic acid (ARA) strengthens rabies-vaccine antibody responses in mice and accelerates neutralizing-antibody development in human volunteers. Its mechanistic findings connect ARA-derived prostaglandin I2 signaling with B-cell activation, while leaving important questions about dose, durability, and applicability to other vaccines unresolved.
-
CD44–Copper Signaling Activates UC Macrophages
2026-09-24
This study links CD44-associated copper accumulation with activation of pro-inflammatory Ly6C-high macrophages in ulcerative colitis models. Its combined dataset analysis, mouse intervention, proteomics, and macrophage experiments point to copper handling and oxidative stress as connected features of inflammation, while leaving the precise molecular steps and clinical relevance for further study.